Company Description
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe.
The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies.
Its lead biologic commercial product candidate is Anktiva, an IL-15 superagonist antibody-cytokine fusion protein for the treatment of bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease.
The company also develops other therapeutic agents for the treatment of liquid and solid tumors, including bladder, lung, colorectal, and ovarian cancers, as well as glioblastoma multiforme, acute myeloid leukemia, and human immunodeficiency virus.
It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., and Viracta Therapeutics, Inc. The company is based in San Diego, California.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 628 |
| CEO | Richard Gerald Adcock |
Contact Details
Address: 3530 John Hopkins Court San Diego, California 92121 United States | |
| Phone | (844) 696-5235 |
| Website | immunitybio.com |
Stock Details
| Ticker Symbol | IBRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326110 |
| CUSIP Number | 45256X103 |
| ISIN Number | US45256X1037 |
| Employer ID | 43-1979754 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc. | Executive Chairman of the Board, Global Chief Scientific and Medical Officer |
| Richard Gerald Adcock | President, Chief Executive Officer and Director |
| David C. Sachs | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Dr. Barry J. Simon M.D. | Chief Corporate Affairs Officer and Director |
| Dr. Leonard S. Sender M.D. | Chief Operating Officer |
| Dr. Enrique Diloné Ph.D., RAC | Chief Technology Officer |
| Jason R. Liljestrom | General Counsel and Corporate Secretary |
| Sarah Singleton | Chief Communications Officer and Head of Patient Advocacy |
| Dr. Sandeep K. Reddy M.D. | Chief Medical Officer |
| Dr. Hans Georg Klingemann M.D., Ph.D. | Chief Science Officer of Cellular |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Mar 29, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 19, 2024 | 10-K | Annual Report |
| Feb 26, 2024 | 8-K | Current Report |
| Jan 4, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jan 2, 2024 | 8-K | Current Report |
| Nov 9, 2023 | 10-Q | Quarterly Report |
| Sep 28, 2023 | DEF 14C | Filing |
| Sep 22, 2023 | D | Notice of Exempt Offering of Securities |
| Sep 21, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |